Annovis Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Annovis Bio, Inc. (ANVS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 777.39 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 747.39K shares.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 30.00K shares.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 200.00K shares.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 220.00K shares, a 74.73% decline from fiscal 2024.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 870.49K shares, a 136.98% increase from fiscal 2023.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 367.33K shares, a 5.47% increase from fiscal 2022.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 348.29K shares, a 35.27% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 747.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 777.39K shares 10-Q · filed 2026-08-14 | 777.39K shares derived: sum of 3 quarters · filed 2026-08-14 | 977.39K shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 30.00K shares 10-Q · filed 2026-05-15 | 30.00K shares derived: sum of 2 quarters · filed 2026-05-15 | 230.00K shares derived: sum of 3 quarters · filed 2026-05-15 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | 200.00K shares derived: sum of 2 quarters · filed 2026-03-13 | 220.00K shares 10-K · filed 2026-03-13 | |
| 2025-09-30 | 200.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 220.00K shares 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | 20.00K shares 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | 870.49K shares 10-K · filed 2026-03-13 | |||
| 2023-12-31 | 367.33K shares 10-K · filed 2025-03-21 | |||
| 2023-03-31 | 81.70K shares 10-Q · filed 2023-05-10 | 81.70K shares derived: sum of 2 quarters · filed 2024-03-29 | 221.71K shares derived: sum of 3 quarters · filed 2024-03-29 | 241.71K shares derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 140.00K shares derived: sum of 2 quarters · filed 2024-03-29 | 160.00K shares derived: sum of 3 quarters · filed 2024-03-29 | 348.29K shares 10-K · filed 2024-03-29 |
| 2022-09-30 | 140.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 160.00K shares derived: sum of 2 quarters · filed 2022-11-08 | 348.29K shares 10-Q · filed 2022-11-08 | 802.19K shares derived: sum of 4 quarters · filed 2023-03-31 |
| 2022-06-30 | 20.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 208.29K shares 10-Q · filed 2022-08-08 | 662.19K shares derived: sum of 3 quarters · filed 2023-03-31 | 746.39K shares derived: sum of 4 quarters · filed 2023-03-31 |
| 2022-03-31 | 188.29K shares 10-Q · filed 2022-05-04 | 642.19K shares derived: sum of 2 quarters · filed 2023-03-31 | 726.39K shares derived: sum of 3 quarters · filed 2023-03-31 | 726.39K shares derived: sum of 4 quarters · filed 2023-03-31 |
| 2021-12-31 | 453.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 538.10K shares derived: sum of 2 quarters · filed 2023-03-31 | 538.10K shares derived: sum of 3 quarters · filed 2023-03-31 | 538.10K shares 10-K · filed 2023-03-31 |
| 2021-09-30 | 84.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 84.20K shares derived: sum of 2 quarters · filed 2021-11-03 | 84.20K shares 10-Q · filed 2021-11-03 | |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | 0.00 shares 10-Q · filed 2021-07-28 | ||
| 2021-03-31 | 0.00 shares 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | 810.00K shares 10-K · filed 2022-03-02 | |||
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-06 | 0.00 shares derived: sum of 2 quarters · filed 2021-05-06 | 0.00 shares derived: sum of 3 quarters · filed 2021-05-06 | 0.00 shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | 0.00 shares derived: sum of 2 quarters · filed 2021-03-03 | 0.00 shares derived: sum of 3 quarters · filed 2021-03-03 | 0.00 shares 10-K · filed 2021-03-03 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-04 | 0.00 shares 10-Q · filed 2020-11-04 | |
| 2019-06-30 | 0.00 shares 10-Q · filed 2020-07-29 | 0.00 shares 10-Q · filed 2020-07-29 | ||
| 2019-03-31 | 0.00 shares 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |